The core purpose of Synaflan (Fluocinonide) is to provide therapeutic support across several domains of inflammatory skin conditions. This preparation may be relevant for easing the symptoms related to inflammatory or irritative states.

Synaflan is commonly used across conditions characterized by periods of heightened symptoms, specifically including Psoriasis, Atopic Dermatitis, and conditions involving inflammatory or irritative processes. It may assist with managing primary symptom clusters such as intense pruritus (severe itching), redness, and swelling that interfere with daily functioning. The medication is often used during phases when symptoms become more noticeable, particularly relevant in situations where symptoms escalate temporarily.

This supportive therapeutic approach contributes to easing discomfort during periods of heightened symptoms, and supports general well-being during symptomatic phases.

Quick Fact:	Supportive Management of Pruritus
Primary Use Focus	Management of chronic inflammatory skin disorders
Goal	Supportive symptom management for episodic manifestations
Key Benefit	Contributes to easing the overall symptom load

Regulatory References

1. DailyMed Fluocinonide Ointment Indications

Official Population Eligibility for Synaflan

Synaflan (Fluocinonide) is a high-potency topical corticosteroid, and its official regulatory labeling strictly defines the populations who can and cannot use the medicine.

Category	Official Regulatory Status
Populations Contraindicated	Patients with known hypersensitivity to the drug's components; Patients with Rosacea or Perioral Dermatitis.
Age-Related Eligibility	Adults are approved for use. For one high-potency formulation, use is established for patients 12 years of age and older.
Use Not Recommended	Pediatric patients younger than 12 years of age for certain formulations, as safety and efficacy are not established.
Pregnancy Status	Pregnancy Category C. Use is conditional; restricted to situations where the potential benefit justifies the potential risk to the fetus.
Lactation Status	Use with caution in nursing mothers is advised.

Conditions Affecting Eligibility

The medicine is contraindicated if a patient has a history of allergic reaction to Fluocinonide or any ingredient in the preparation. Furthermore, Rosacea and Perioral Dermatitis are absolute contraindications, and Synaflan must not be used to treat these conditions.

Pediatric patients have a greater risk of systemic toxicity due to higher absorption, and caution is required for patients with pre-existing metabolic or endocrine disorders, such as HPA axis suppression or hyperglycemia, as systemic absorption may worsen these conditions.

The interaction profile of Synaflan (Fluocinonide topical) is officially defined by its pharmacodynamic properties as a high-potency corticosteroid, focusing primarily on the risk of increased systemic exposure when co-administered with other products of the same class.

The core documented interaction is with other corticosteroid-containing products. Co-administration may increase the total systemic glucocorticoid exposure due to the additive nature of systemic absorption, which is officially classified as an exposure-modifying interaction. Conditions that augment systemic absorption, such as the use of occlusive dressings or application to large surface areas, also contribute to this exposure risk.

The official profile does not list any specific drug-drug combinations as formally contraindicated, and there are no documented timing-based separation rules required for administration. Regulatory documents do not specify any explicit CYP-mediated or transporter-based metabolic interactions for this topical formulation.

Concerning food and substances, official data states there are no known interactions with specific foods or drinks. The effect of alcohol consumption on the systemic absorption of this topical product is noted as unknown.

A population-specific note exists for pediatric patients. Children may exhibit greater susceptibility to the systemic effects of corticosteroids due to a higher skin surface area to body weight ratio, thus increasing the clinical relevance of the additive glucocorticoid exposure risk.

Synaflan, which corresponds to the agent fluocinolone acetonide, exerts its primary action by functioning as an agonist at the intracellular Glucocorticoid Receptor (GR). The lipophilic molecule enters the target cell membrane and binds to the cytosolic GR, displacing heat shock proteins. This receptor-ligand complex then undergoes translocation into the cell nucleus.

Within the nucleus, the complex interacts with specific Glucocorticoid Response Elements (GREs) in the promoter regions of target genes, thereby modulating gene transcription. This genomic mechanism primarily results in the transactivation of genes encoding anti-inflammatory proteins, such as Annexin A1 (also known as lipocortin-1). Transactivation also occurs for genes encoding Ikappa Balpha, which sequesters the NF-kappa B transcription factor.

Conversely, the drug-receptor complex mediates transrepression of genes that encode pro-inflammatory mediators, including various cytokines and chemokines. The increased expression of Annexin A1 leads to the inhibition of phospholipase A2 ( PLA2), an enzyme critical for releasing arachidonic acid from cell membrane phospholipids. This PLA2 inhibition results in a downstream attenuation of the biosynthesis of eicosanoids, specifically prostaglandins and leukotrienes. These combined genomic and non-genomic actions lead to system-level modulation of immune and vascular responses, including vasoconstriction and decreased leukocyte extravasation.

Synaflan, which contains the high-potency corticosteroid Fluocinonide, is designated strictly for topical administration to the skin. The general principle of use follows a short-term, high-intensity regimen to manage inflammatory skin disorders. The medication is applied as a thin film or thin layer directly to the affected area.

The standard labeled dosing frequency varies by concentration and formulation. For the 0.05% forms (Ointment, Gel, Solution), application is typically directed two to four times daily. The 0.1% cream formulation, when used for specific conditions, may be applied once or twice daily.

Standard guidelines specify strict limits on the duration and quantity of application. Treatment is typically restricted to a maximum of 2 consecutive weeks and the total amount used should not exceed 60 grams per week. Use should be discontinued promptly once the affected area is under control, and the regimen must be re-evaluated if no improvement is observed within the two-week timeframe.

Administration requires procedural constraints; application on the face, groin, or axillae is generally avoided. Furthermore, the use of occlusive dressings is largely discouraged as a matter of standard practice unless a specific recalcitrant condition necessitates this approach under medical direction. For pediatric patients, administration should be limited to the least amount necessary for efficacy, consistent with established protocols.

Research evidence / Overview of studies for Synaflan

Evidence for use in Corticosteroid-Responsive Dermatoses

The foundational clinical evaluation for Synaflan (Fluocinonide) was conducted through short-term, vehicle-controlled Randomized Controlled Trials (RCTs). This type of research explored how symptom patterns were measured during the course of the study. The medicine was studied for how symptoms evolved in the observed populations over defined two-week intervals.

In these trials, researchers primarily measured the Investigator's Global Assessment (IGA) score to describe the condition of the skin lesions. Studies reported measurements of how these overall assessment scores evolved during the observation period. Specialized studies monitored serum cortisol levels to check for patterns related to physiological strain or stress on the body's internal systems (the HPA axis).

However, the results apply only to the populations studied and the brief time frame of the pivotal trials. Long-term effects are not fully established, and there is limited information for long-term outcomes or repeated use beyond the short treatment window.

---

Research evidence for Plaque-type Psoriasis

The research base for plaque-type psoriasis includes both short-term, vehicle-controlled RCTs and longer-term, non-interventional observational studies. The RCTs focused on studies exploring short-term symptom changes over defined time intervals. This medicine was evaluated in subjects with a condition characterized by fluctuating or episodic manifestations.

In these trials, research examined outcomes using validated tools like the Psoriasis Area and Severity Index (PASI) score and the IGA. Findings describe patterns observed in the studies over the short treatment interval, including metrics measured in both the active medication group and the vehicle control group.

---

Clinical evaluation for Atopic Dermatitis (Eczema)

Clinical trials for atopic dermatitis included short-term, randomized, vehicle-controlled studies and research exploring different application schedules. Studies monitored clinical disease metrics, such as the Eczema Area and Severity Index (EASI) score and the IGA score, over the two-week period. Research also describes patterns related to symptom intensity, including measurements from the Visual Analog Scale (VAS) for itch.

---

What is Still Uncertain About the Research Record

The existing evidence base highlights several areas where certainty remains low. One primary research limitation frame is the short duration of the core clinical evaluation. This leads to limited information for long-term outcomes regarding both the clinical evaluation and systemic safety. Data are still emerging regarding certain subgroups, and comparative evidence is lacking in some study designs that directly assess this formulation against every other specific topical steroid.

Key Studies & References Fluocinonide Ointment, 0.05% Topical: Official Labeling and Monograph

Common questions about Synaflan (FAQ)

Q: What is the longest period of time Synaflan has been studied for continuous use?

A: Regulatory documents indicate that treatment is generally not recommended for use beyond 2 consecutive weeks. Official documentation indicates that the total amount used is restricted to a maximum of 60 grams per week. This limitation is based on the safety and efficacy established during the core clinical evaluation.

Q: Do any official documents state that Synaflan is only intended for short-term use?

A: Yes, official recommendations strongly suggest a limited duration of use. Treatment safety and efficacy beyond 2 consecutive weeks have not been established, which defines the intended use of the medicine as a short-term regimen for the relief of inflammatory skin conditions.

Q: Is Synaflan available over the counter, or is it prescription-only?

A: Official labeling for Synaflan designates the medicine as Rx only. This means it is a prescription-only drug and is not available for purchase over the counter.

Q: Do I need to take Synaflan with food or can I take it on an empty stomach?

A: Synaflan is an external medication intended only for topical application to the skin. Official data regarding interactions indicates that there are no known interactions with specific foods or drinks, due to the product’s design for external application.

Q: Are there any dietary restrictions mentioned in the official documents for Synaflan?

A: No, official regulatory documents state there are no known interactions with specific foods or drinks that would necessitate dietary restrictions while using this topical medicine.

Q: Can Synaflan be crushed or split if a person has trouble swallowing pills?

A: Synaflan is an external medication for topical administration only, available as a cream, ointment, gel, or solution. It is not an oral medication (pill) that is designed to be swallowed, crushed, or split.

Q: What is the purpose of the colored coating on the Synaflan tablet?

A: Synaflan is a topical medication available as a cream, ointment, gel, or solution for external use on the skin. The medicine is not manufactured as an oral tablet with a coating.

Q: What is the official recommended storage temperature for Synaflan?

A: The official product information specifies that the medicine should be stored at controlled room temperature. This temperature range is defined as being specifically between 20°C to 25°C (68°F to 77°F).

Q: What are the general expectations for benefits when using Synaflan?

A: According to official documents, the drug is indicated for the relief of the inflammatory and pruritic manifestations (itching) associated with corticosteroid-responsive dermatoses. The drug is designated to provide relief from both inflammation and associated itching.

Q: What are the known potential effects of Synaflan on fertility?

A: Official data indicates that long-term animal studies have not been performed to evaluate the drug's potential effects on fertility. Therefore, the long-term impact on human fertility is not fully established in regulatory documents.

Q: Can Synaflan be used by people who are actively breastfeeding?

A: Official labeling advises that it is not known if the topical use of this medicine results in high enough systemic absorption to produce detectable quantities in breast milk. Official guidance notes that the importance of the medicine to the mother should be considered when determining use while nursing.

Q: Why is Synaflan not recommended for pregnant women?

A: The drug is classified as Pregnancy Category C. This classification is based on studies showing that corticosteroids can be teratogenic (cause developmental malformations) in laboratory animals when administered systemically at relatively low doses.

Q: Is Synaflan associated with any rare but serious warnings in its documentation?

A: Yes, regulatory warnings highlight the rare but serious potential for Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and Cushing's syndrome due to systemic absorption. In children, the risk of intracranial hypertension is also listed as a serious potential warning.

Q: Why are people with a specific pre-existing condition advised against taking Synaflan?

A: The medicine is specifically contraindicated for patients with conditions such as Rosacea or Perioral Dermatitis. Caution is also advised for those with pre-existing conditions like HPA axis suppression because systemic absorption of the medicine may worsen these conditions.

Q: What kind of monitoring is recommended while taking Synaflan?

A: Official documentation describes the need for periodic evaluation for signs of HPA axis suppression in patients who use the medicine over a large surface area or under an occlusive dressing. This evaluation often involves specific laboratory tests, such as the ACTH stimulation test or the Urinary free cortisol test.

Q: Does Synaflan affect the outcome of any laboratory tests?

A: Systemic absorption of the medicine may affect the hypothalamic-pituitary-adrenal (HPA) axis. This is monitored using specific laboratory tests, such as the ACTH stimulation test, to check for proper adrenal function.

Q: Is it normal to feel slightly dizzy when first starting Synaflan?

A: Dizziness is a symptom that has been documented in association with potential systemic side effects, such as HPA axis suppression. These systemic effects are rare but can occur due to drug absorption through the skin.

Q: Can Synaflan affect a person's mood or sleep patterns?

A: Systemic absorption may rarely lead to conditions like adrenal insufficiency or Cushing's syndrome, whose symptoms can include changes in mood. Documented mood changes include irritability, anxiety, and depression.

Q: What happens to the body if a person suddenly stops taking Synaflan?

A: The body may rarely experience signs and symptoms of steroid withdrawal upon discontinuation of the medicine, which is a recognized possibility with systemic steroid exposure. In some cases, this reaction may require temporary supplemental systemic corticosteroids.

Q: How long does Synaflan stay in the body after the last use?

A: The systemically absorbed component of the drug, while minimal, has a documented elimination half-life ranging between 1.3 to 1.7 hours. The half-life is the time it takes for half of the substance to be eliminated from the body.

Q: Is Synaflan safe for people who have kidney issues?

A: Once the medicine is absorbed, topical corticosteroids are metabolized in the liver and then excreted by the kidneys. The extent to which pre-existing kidney issues affect the systemic clearance of this topical medication is not explicitly detailed in the warnings.

Q: How does Synaflan interact with birth control pills?

A: Official regulatory documents do not list specific metabolic or transporter-based interactions with oral contraceptives. The core documented drug interaction is with other corticosteroid-containing products.

Q: Are there any known interactions between Synaflan and common pain relievers like ibuprofen?

A: Official regulatory labels do not list specific metabolic or transporter-based interactions with common pain relievers like Ibuprofen. The only core documented interaction is with other corticosteroid-containing products.

Q: Can Synaflan be taken alongside vitamin supplements?

A: Official documents do not list specific drug-vitamin interactions. The only core documented interaction is with other corticosteroid-containing products, meaning no formal warnings exist for co-administration with vitamins.

Storage and Disposal of Synaflan (Fluocinonide)

Synaflan must be stored at controlled room temperature, specifically maintained between 20°C to 25°C (68°F to 77°F), with permitted temperature excursions up to 30°C. It is a mandatory requirement to keep the medicine in its original container, ensuring the tube is tightly closed when not in use. The product must be protected from environmental extremes; it is strictly prohibited to freeze the medication or expose it to excessive heat or moisture.

For safety, the medicine must be stored out of the sight and reach of children.

Regarding disposal, patients are instructed not to keep outdated medicine. The regulatory guidance requires consulting a healthcare professional or pharmacist for proper instructions on discarding any unused or expired product.